Cosentyx unoready 300 MG pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F56ZL
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $178,851
Award facts
- Contract value 100% obligated
- $178,850.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 26, 2025, for the supply of Cosentyx (secukinumab) 300 mg pre-filled pens in 2 mL formulations, with a ceiling value of $178,850.88. This is a firm fixed-price delivery order with an ultimate completion date of December 29, 2025, and was awarded without a set-aside designation through open competition. The contract is executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026 that serves as a comprehensive pharmaceutical support vehicle for military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order as part of its extensive federal contract portfolio supplying the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems with specialty medications, vaccines, and medical supplies across multiple therapeutic domains. The company's history of competitive awards and firm fixed-price delivery orders demonstrates its capability to meet federal medical procurement requirements efficiently. Cosentyx is a biologic immunosuppressant used primarily in the treatment of autoimmune conditions such as psoriasis and rheumatoid arthritis, indicating this procurement supports military healthcare beneficiaries requiring specialized pharmaceutical therapies.
Quick answers
Who was awarded contract SPE2DR26F56ZL?
SPE2DR26F56ZL was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 26, 2025.
How much is contract SPE2DR26F56ZL worth?
The government has obligated $178,851 on SPE2DR26F56ZL.
Is contract SPE2DR26F56ZL an order under another contract?
Yes. SPE2DR26F56ZL is a delivery order under SPE2DR25D2006, an indefinite delivery contract.
Was contract SPE2DR26F56ZL competed?
The extent of competition for SPE2DR26F56ZL was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award